Experimental antibody targets childhood cancers in first human trial
NCT ID NCT04928677
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a drug called codrituzumab in children and young adults (ages 1 to 21) whose solid tumors have come back or not responded to treatment and carry a specific protein called GPC3. The main goal is to find a safe dose and see how the body handles the drug. Up to 50 participants will receive weekly IV infusions for 21-day cycles.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- codrituzumab (a lab-made antibody that targets GPC3 protein on tumor cells)
- What this could lead to
- If it works, this could point toward a treatment for children with certain hard-to-treat solid tumors that have not responded to standard therapy.
- What could go wrong
- This is a very early Phase 1 trial with only 50 participants, so the main goal is safety, not effectiveness. The drug may not shrink tumors or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY EXTRA-CRANIAL SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Healthcare of Atlanta (Data Collection Only)
RECRUITINGAtlanta, Georgia, 30322, United States
-
Children's Hospital of Los Angeles (Data Collection Only)
RECRUITINGLos Angeles, California, 90027, United States
-
Cincinnati Children's Hospital Medical Center
RECRUITINGCincinnati, Ohio, 45229, United States
-
Dana Farber Cancer Institute (Data Collection Only)
RECRUITINGBoston, Massachusetts, 02115, United States
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States